Biodesix, Inc. (BDSX) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BDSX Revenue Growth
Revenue Breakdown (FY 2025)
BDSX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
BDSX Revenue Analysis (2018–2025)
As of May 8, 2026, Biodesix, Inc. (BDSX) generated trailing twelve-month (TTM) revenue of $96.1 million, reflecting explosive growth of +42.3% year-over-year. The most recent quarter (Q1 2026) recorded $25.6 million in revenue, down 11.1% sequentially.
Looking at the longer-term picture, BDSX's 5-year compound annual growth rate (CAGR) stands at +14.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $88.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows BDSX's business is primarily driven by Diagnostic Tests (89%), and Development Services (11%). With over half of revenue concentrated in Diagnostic Tests, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including EXAS (+17.7% YoY), NTRA (+35.9% YoY), and VCYT (+16.9% YoY), BDSX has outperformed the peer group in terms of revenue growth. Compare BDSX vs EXAS →
BDSX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BDSXCurrent | $96M | +42.3% | +14.2% | -31.5% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 ONCO | $815,371 | -67.7% | - | -778.2% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
BDSX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $88.5M | +24.1% | $66.6M | 75.2% | $-27,873,000 | -31.5% |
| 2024 | $71.3M | +45.3% | $55.8M | 78.2% | $-34,498,000 | -48.4% |
| 2023 | $49.1M | +28.5% | $36.1M | 73.5% | $-41,342,000 | -84.2% |
| 2022 | $38.2M | -29.9% | $24.1M | 63.0% | $-50,587,000 | -132.4% |
| 2021 | $54.5M | +19.6% | $24.0M | 44.0% | $-40,940,000 | -75.1% |
| 2020 | $45.6M | +85.6% | $23.6M | 51.7% | $-22,934,000 | -50.3% |
| 2019 | $24.6M | +20.2% | $18.5M | 75.3% | $-26,741,000 | -108.9% |
| 2018 | $20.4M | - | $16.0M | 78.4% | $-23,461,000 | -114.8% |
See BDSX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDSX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDSX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBDSX — Frequently Asked Questions
Quick answers to the most common questions about buying BDSX stock.
Is BDSX's revenue growth accelerating or slowing?
BDSX revenue is accelerating at +42.3% year-over-year, exceeding the 5-year CAGR of +14.2%. TTM revenue reached $96M. Growth momentum has increased versus prior periods.
What is BDSX's long-term revenue growth rate?
Biodesix, Inc.'s 5-year revenue CAGR of +14.2% reflects the sustained expansion pattern. Current YoY growth of +42.3% is above this long-term average.
How is BDSX's revenue distributed by segment?
BDSX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.